# A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

> **NCT01285323** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 464 (actual)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **DRUG:** Reslizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01285323
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285323, "A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01285323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*